Compare CSBR & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | DRIO |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 56.8M |
| IPO Year | 2015 | 2013 |
| Metric | CSBR | DRIO |
|---|---|---|
| Price | $4.90 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.60 |
| AVG Volume (30 Days) | 12.8K | ★ 14.9K |
| Earning Date | 09-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1559.02 |
| EPS | N/A | ★ 1.75 |
| Revenue | $2,900,000.00 | ★ $7,394,000.00 |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $8.50 | $38.77 |
| P/E Ratio | ★ N/A | $3.10 |
| Revenue Growth | N/A | ★ 43.02 |
| 52 Week Low | $4.59 | $5.33 |
| 52 Week High | $8.31 | $16.50 |
| Indicator | CSBR | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 34.83 |
| Support Level | $4.81 | N/A |
| Resistance Level | $6.29 | $8.01 |
| Average True Range (ATR) | 0.16 | 0.44 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 45.65 | 10.96 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.